The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Been numerous mid-point transactions over the last while with 10,000 traded on a regular basis. Often appears to the close. No doubt there is another explanation other than at negotiated trade by River Fort. Would not be a bad way of releasing some shares remaining shares.
Must say that an air of optimism has returned. Director buys and the good safety demonstrated by the 1st three cohorts would be the catalyst. Hugely important has been the superb research and commetry and analysis by many on this board in sharing information, insights andpppll keppppppeping spirits up. As Celtic says let the science do the talking. I'm personally very optimistic going forward.
Second day running that the buys outstripped the sells, by a margin of 3:1 today, without any increase in price at the close. Imagine if the reverse was the case. Wondering if they want the two headed snake to sliver back. Lowering the price after 2.30 had no rhyme nor reason.
Great Post SOG. Agree that safety data on dose escalation phase of SDC 1801 is pivotal in relation to a licence or partnership. One hopes that CPF are close to an on license deal in combo therapy for 737. A complete buyout however would be my desired outcome, taking the ongoing suspense and time element out of the equation.
With good safety results, including good mtd, I believe that SAR are going to be a highly attractive proposition indeed for major pharma companies.
Correct me potnak if I'm not accurate but I recall a post by you from some time back suggesting that effacy phase should be a walk in the park if safety was good. Some time ago so could be mistaken ? I believe from todays RNS thatwe are on our way to establishing good tox results.
Has to be seen as a steady as she goes RNS. Taking it that we are doing well in P1a so far and that the second phase, multiple escalating dose, is pretty nailed on to happen. What is very important here is the decision by the safety committee in relation to maximum dose allowed in the multiple phase of P1a. SOG , if I'm quoting him correctly believes that the maximum dose allowed will have a major bearing on future indications that 1801 could be applied to. We will also be getting this information shortly,as per the RNS. So far so very good.
After the clever unsuccessful short attempt by our new guests over the last few days it is important for the BOD to communicate with us in a timely way on the three huge issues that will reassure. A timely update on the escalation studies currently ongoing on 1801, an indication that chk1 talks are progressiplng with interested parties and yhe anticipated timeliness for completion of 1801 preclinical. Positive updates in those areas would greatly help to settle lingering anxiety and the SP.
Agree that this represents a vote of confidence in Sareum going forward.We are on the cusp of getting initial safety data from phase 1a clinical trial.This suggests confidence that the trial is progressing well. Agree with Num 4 in relation to improving sentiment, for which the next RNS should copperfashion. I would think it unlikely that funding would arrive at this point if the outlook was not positive. Seems like a vote of confidence.
Great that part 1 of the trial is pretty much completed with no reported adverse affects from SAR. I could be wrong but the RNS from SAR on the 6th June announcing dosing of the first subjects states "The company expects to provide a further update on the trial once initial safety and pharmacokinetic data observed in the single dose studyprovide sufficient support for progression to part 2of the study, expected in H2 2023.
In an earlier section of same RNS it states ' part 2 (multiple ascending dose) is planed to commence after the safety review Committee (SRC) has evaluated the available data from at least A,B and C in Part 1.(single ascending dose)
I read that as the 1st three 8 person groups, ie 24 of the 32 subjects. It may be we will have to wait a little for official confirmation. I sincerely hope that SAR will issue an RNS very soon indeed but I know that the BOD will follow the correct procedures.
Good luck all genuine holders.
Good article Citizen 79. Goes to show that wiit innovative drugs in sought after markets, a la Sareum, even at preclinical stage, the Pharmas, with their approaching patents and need for futuristic drugs In lucrative fields will come knocking. That's even in the present financially challenging times.